News


  • 06 March 2018

    Clearside Announces Proposed Public Offering of Common Stock

    Clearside Announces Proposed Public Offering of Common Stock

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it intends to offer and sell, subject to market conditions,  $75 million  of shares of its common stock in an underwritten public offering.  All of the shares of common stock to be sold in the offering will be offered by Clearside.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

  • 06 March 2018

    Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results

    Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2017.

  • 06 March 2018

    Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

    Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 3 clinical trial (“TOPAZ”) of suprachoroidal CLS-TA used with an intravitreally administered anti-VEGF agent (“intravitreal anti-VEGF agent”) for the treatment of macular edema associated with Retinal Vein Occlusion (“RVO”).

  • 05 March 2018

    Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2017. In addition, the Company provided a clinical and business update. As of December 31, 2017, Syndax had $133.2 million in cash, cash equivalents and short-term investments.

  • 05 March 2018

    Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis

    Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis. 

  • 28 February 2018

    Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DXЃ AR-V7 Nucleus DetectЩ Test to Predict Treatment Response in Metastatic Disease

    Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DXЃ AR-V7 Nucleus DetectЩ Test to Predict Treatment Response in Metastatic Disease

    Genomic Health, Inc. (NASDAQ:  GHDX) today announced the U.S. commercial launch of the Oncotype DX® AR-V7 Nucleus Detect™ test. The first and only liquid biopsy test of its kind, the Oncotype DX AR-V7 Nucleus Detect test was developed by Epic Sciences to help prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC) by accurately detecting a splice variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells (CTCs). 

  • 26 February 2018

    Clearside Biomedical Announces Organizational Changes Designed to Support Transition to a Commercial-Stage Company

    Clearside Biomedical Announces Organizational Changes Designed to Support Transition to a Commercial-Stage Company

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the appointments of William (“Bill”) Humphries as the new Chairman of the Board and  Brion Raymond as Chief Commercial Officer.  These appointments are intended to further prepare the company for the potential commercialization of CLS-TA for suprachoroidal administration (“suprachoroidal CLS-TA”), its proprietary suspension formulation of the corticosteroid triamcinolone acetonide for the treatment of macular edema associated with non-infectious uveitis. 

  • 21 February 2018

    Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia

    Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia

    Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of urogenital chlamydia in women.

  • 20 February 2018

    Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule

    Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule

    Evofem Biosciences, Inc., (NASDAQ: EVFM), a biotechnology company developing innovative products to fill women's unmet healthcare needs, announced early completion of enrollment in its Phase 3 clinical trial evaluating Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of pregnancy. Trial data is expected in the first quarter of 2019.

  • 08 February 2018

    Epic Sciences To Present Single Cell PSMA Analysis To Provide Insight Into Tumor Heterogeneity And Links To Response With Anti-PSMA Therapy

    Epic Sciences To Present Single Cell PSMA Analysis To Provide Insight Into Tumor Heterogeneity And Links To Response With Anti-PSMA Therapy

    Epic Sciences, Inc. (Epic) announces that it will present data, in conjunction with Endocyte, Inc., comparing its proprietary single cell CTC analysis to PSMA targeted imaging in mCRPC patients to provide insight into disease heterogeneity and identify potential therapeutic resistance mechanisms.